Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma
Status:
Completed
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well vorinostat works in treating patients with adenoid
cystic carcinoma that has come back (recurrent) or that has spread from where it started to
nearby tissue or lymph nodes (locally advanced) or has spread to other places in the body
(metastatic). Vorinostat may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth.